Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 02/03/2014 - 02/03/2016

This course is closed. Please look for other available products in CPNP University.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of schizophrenia and movement disorders. Content includes a comprehensive outline and author presentation focused on etiology, risk factors, pathophysiology and treatment of schizophrenia and movement disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)
  • Select the ACCME credit option when submitting the post-test if you desire CME credit rather than ACPE credit.

This course is provided online at cpnp.org and is available to participants through the course expiration date. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe. ACCME statements are printable immediately upon successful completion of this course.

Faculty Information and Disclosures

Heidi J. Wehring, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Describe the clinical presentation, signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia and movement disorders.
  2. Explain the use of common rating scales for research (DII), diagnosis, and management of schizophrenia and movement disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options in the acute and long-term management of schizophrenia and movement disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities and black box warnings) for drugs used in schizophrenia and movement disorders. 
  5. Describe treatment guidelines (DIII) and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice (DII) for schizophrenia.
  6. Select an evidenced-based drug therapy regimen (drug, dose, schedule, time to response, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of schizophrenia and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy (DII), including strategies for adherence and organizations that advocate and provide resources (DIII) for individuals with schizophrenia.

Continuing Education Credit and Disclosures

Activity Dates: 02/03/2014 - 02/03/2016
ACPE Contact Hours: 2.0
ACPE Number: 0284-9999-14-044-H01-P (Knowledge)
ACCME:2 AMA PRA Category 1 Credit(s)™
Nursing Credit Reminder: Note that ACPE or ACCME credit is accepted for certification renewal.

Continuing Pharmacy Education Credit

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.20 CEUs) of knowledge-based continuing education credit. The ACPE universal program number assigned to this course is 0284-9999-14-044-H01-P (2.0 contact hours).

Continuing Medical Education Credit

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

CEC designates this enduring material educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grant Support

This activity is supported by an educational grant from Lilly and Sunovion Pharmaceuticals Inc. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.